Additional Clinical Reports of OvaScience AUGMENT Fertility Treatment Show Improved Pregnancy Rates in Women with Multiple Prior Failed IVF Cycles
Kutluk Oktay, M.D., F.A.C.O.G, of Gen-art IVF in
“These initial AUGMENT pregnancy rates are quite encouraging, especially given that these were women who had failed multiple IVF cycles and were running out of options to use their own eggs,” said Dr. Oktay. “We were also pleased to see these pregnancy rates achieved with single embryo transfers during IVF, a practice that may limit the number of multiple births, which can cause health risks to the mother and infant during pregnancy and delivery and after. Based on our experiences to date, the AUGMENT treatment appears to benefit women with poor egg quality and we look forward to continuing to share our clinical experiences.”
The results reported in the poster presentation represent experiences
from a small number of patients with different diagnoses, ages and prior
IVF history. As of this reporting, pregnancy rates across IVF clinics
that offer the AUGMENT treatment currently range from 25% - 53%, which
includes clinics that are treating some of the more challenging
The AUGMENT treatment is a fertility treatment specifically designed to use the mitochondria, or energy, from a woman’s own egg precursor cells – immature egg cells found inside the protective ovarian lining – to improve egg health. The treatment is available to patients in select international IVF clinics. Additional information can be found at www.augmenttreatment.com.
“The positive clinical evidence continues to build in support of our
AUGMENT treatment,” stated
Dr. Oktay’s poster presentation follows an AUGMENT presentation made by
This press release includes forward-looking statements about the Company’s plans for the AUGMENT treatment and future pregnancy rates. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: the possibility that international IVF clinics that we work with may determine not to begin or continue providing the AUGMENT treatment for commercial or other reasons; our expectation that the AUGMENT treatment and OvaPrime treatment meet the requirements of a class of products exempt from premarket review and approval under applicable regulations in those countries where we have launched or plan to introduce the AUGMENT treatment and plan to introduce the OvaPrime treatment; the commercial ramp up of the AUGMENT treatment, which we expect will depend upon the successful transition of ACE clinics to commercial operations, the addition of new ACE clinics, and the results from ACE clinic experience as they become available; the science underlying our treatment and treatments in development (including the AUGMENT, OvaPrime and OvaTure treatments), which is unproven; our ability to obtain regulatory approval where necessary for our potential treatments; our ability to develop our potential treatments, including the OvaPrime and OvaTure treatments, on the timelines we expect, if at all; our ability to commercialize the AUGMENT treatment and our potential treatments, including the OvaPrime treatment, on the timelines we expect, if at all; as well as those risks more fully discussed in the “Risk Factors” section of our most recently filed Quarterly Report on Form 10-Q and/or Annual Report on Form 10-K. The forward-looking statements contained in this press release reflect our current views with respect to future events. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our view as of any date subsequent to the date hereof.
1 Outcomes presented show percentage of clinical pregnancies from embryo transfer.
2 Clinical pregnancy is defined as a pregnancy diagnosed by ultrasound. http://www.eshre.eu/Guidelines-and-Legal/ART-glossary.aspx